TScan Therapeutics, Inc. (TCRX) stock
TCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/3089% below fair value
$0.15+0.01 (+4.07%)
Close on Nov 17, 2026Market cap $10.23MP/E –Yield –
TScan Therapeutics cash
Cash and short-term investments held at the end of each period.
TScan Therapeutics's cash was $100.16M at Jun 30, 2026. For fiscal 2025 it was $152.41M, down 48.4% from the year before. The highest annual figure on record is $295.14M in fiscal 2024.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $152.41M | -48.4% |
| FY2024 | Dec 31, 2024 | $295.14M | +49.8% |
| FY2023 | Dec 31, 2023 | $197.08M | +57.6% |
| FY2022 | Dec 31, 2022 | $125.06M | -24.9% |
| FY2021 | Dec 31, 2021 | $166.44M | +370.3% |
| FY2020 | Dec 31, 2020 | $35.39M | -16.5% |
| FY2019 | Dec 31, 2019 | $42.36M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $100.16M | -54.1% |
| Q1 FY2026 | Mar 31, 2026 | $128.06M | -49.1% |
| Q4 FY2025 | Dec 31, 2025 | $152.41M | -48.4% |
| Q3 FY2025 | Sep 30, 2025 | $184.45M | -32.0% |
| Q2 FY2025 | Jun 30, 2025 | $218.05M | -26.8% |
| Q1 FY2025 | Mar 31, 2025 | $251.69M | +54.6% |
| Q4 FY2024 | Dec 31, 2024 | $295.14M | +49.8% |
| Q3 FY2024 | Sep 30, 2024 | $271.12M | +25.9% |
| Q2 FY2024 | Jun 30, 2024 | $297.68M | +42.5% |
| Q1 FY2024 | Mar 31, 2024 | $162.78M | +70.3% |
| Q4 FY2023 | Dec 31, 2023 | $197.08M | +57.6% |
| Q3 FY2023 | Sep 30, 2023 | $215.42M | +56.9% |
| Q2 FY2023 | Jun 30, 2023 | $208.84M | +66.3% |
| Q1 FY2023 | Mar 31, 2023 | $95.61M | -32.1% |
| Q4 FY2022 | Dec 31, 2022 | $125.06M | -24.9% |
| Q3 FY2022 | Sep 30, 2022 | $137.31M | -24.7% |
| Q2 FY2022 | Jun 30, 2022 | $125.60M | +18.3% |
| Q1 FY2022 | Mar 31, 2022 | $140.84M | +15.9% |
| Q4 FY2021 | Dec 31, 2021 | $166.44M | +370.3% |
| Q3 FY2021 | Sep 30, 2021 | $182.31M | +313.6% |
| Q2 FY2021 | Jun 30, 2021 | $106.20M | +107.4% |
| Q1 FY2021 | Mar 31, 2021 | $121.50M | +186.8% |
| Q4 FY2020 | Dec 31, 2020 | $35.39M | – |
| Q3 FY2020 | Sep 30, 2020 | $44.08M | – |
| Q2 FY2020 | Jun 30, 2020 | $51.21M | – |
| Q4 FY2019 | Dec 31, 2019 | $42.36M | – |
See a number that looks wrong?